BET inhibitor OTX015 targets BRD2 and BRD4 and decreases c-MYC in acute leukemia cells

Marie-Magdelaine Coudé(Hôpital Saint-Louis), Claude Gardin(Sorbonne Université)

Oncotarget

May 14, 2015

10.18632/oncotarget.4131

Cited by 267

Related Papers

A Randomized Comparison of All Transretinoic Acid (ATRA) Followed by Chemotherapy and ATRA Plus Chemotherapy and the Role of Maintenance Therapy in Newly Diagnosed Acute Promyelocytic Leukemia

|Blood|1999|745

Gemtuzumab ozogamicin for <i>de novo</i> acute myeloid leukemia: final efficacy and safety updates from the open-label, phase III ALFA-0701 trial

|Haematologica|2018|349

Prognostic impact of<i>DDX41</i>germline mutations in intensively treated acute myeloid leukemia patients: an ALFA-FILO study

|Blood|2022|80

Fractionated Inotuzumab Ozogamicin Combined with Low-Intensity Chemotherapy in Older Patients with Newly Diagnosed CD22+ Philadelphia Chromosome (Ph)-Negative B-Cell Precursor (BCP) Acute Lymphoblastic Leukemia (ALL): Results of the EWALL-INO Study

|Blood|2022|32

UBTF tandem duplications define a distinct subtype of adult de novo acute myeloid leukemia

|Leukemia|2023|30